Discovery of highly potent and ALK2/ALK 1 selective kinase inhibitors using DNA- encoded chemistry technology

被引:0
|
作者
Jimmidi, Ravikumar [1 ,2 ]
Monsivais, Diana [1 ,2 ]
Ta, Hai Minh [1 ,2 ]
Sharma, Kiran L. [1 ,2 ]
Bohren, Kurt M. [1 ,2 ]
Chamakuri, Srinivas [1 ,2 ]
Liao, Zian [1 ,2 ,3 ]
Li, Feng [1 ,2 ,4 ]
Hakenjos, John M. [1 ,2 ]
Li, Jian - Yuan [1 ,2 ]
Mishina, Yuji [5 ]
Pan, Haichun
Qin, Xuan [1 ,2 ]
Robers, Matthew B. [6 ]
Sankaran, Banumathi [7 ]
Tan, Zhi [1 ,2 ]
Tang, Suni [1 ,2 ]
Vasquez, Yasmin M. [1 ,2 ]
Wilkinson, Jennifer [6 ]
Young, Damian W. [1 ,2 ,8 ]
Palmer, Stephen S. [1 ,2 ]
Mackenzie, Kevin R. [1 ,2 ,8 ]
Kim, Choel [1 ,2 ,8 ]
Matzuk, Martin M. [1 ,2 ,3 ,4 ,8 ]
机构
[1] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[5] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA
[6] Promega Corp, Madison, WI 53711 USA
[7] Lawrence Berkeley Natl Lab, Berkeley Ctr Struct Biol, Mol Biophys & Integrated Bioimaging, Berkeley, CA 94720 USA
[8] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Pharmacol, Houston, TX 77030 USA
关键词
DEL; kinase inhibitors; X- ray Crystallography; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; TRANSFORMING GROWTH FACTOR-BETA-1; CHEMICAL LIBRARIES; ACVR1; MUTATIONS; BMP RECEPTOR; PROTEIN; BINDING;
D O I
10.1073/pnas.2413108121
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Activin receptor type 1 (ACVR1; ALK2) and activin receptor like type 1 (ACVRL1; ALK1) are transforming growth factor beta family receptors that integrate extracellular signals of bone morphogenic proteins (BMPs) and activins into Mothers Against Decapentaplegichomolog 1/5 (SMAD1/SMAD5) signaling complexes. Several activating mutations in ALK2 are implicated in fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine gliomas, and ependymomas. The ALK2 R206H mutation is also present in a subset of endometrial tumors, melanomas, non-small lung cancers, and colorectal cancers, and ALK2 expression is elevated in pancreatic cancer. Using DNA- encoded chemistry technology, we screened 3.94 billion unique compounds from our diverse DNA- encoded chemical libraries (DECLs) against the kinase domain of ALK2. Off- DNA synthesis of DECL hits and biochemical validation revealed nanomolar potent ALK2 inhibitors. Further structure-activity relationship studies yielded center for drug discovery (CDD)-2789, a potent [NanoBRET (NB) cell IC50: 0.54 mu M] and metabolically stable analog with good pharmacological profile. Crystal structures of ALK2 bound with CDD-2281, CDD-2282, or CDD-2789 show that these inhibitors bind the active site through Van der Waals interactions and solvent- mediated hydrogen bonds. CDD-2789 exhibits high selectivity toward ALK2/ALK1 in KINOMEscan analysis and NB K192 assay. In cell- based studies, ALK2 inhibitors effectively attenuated activin A and BMP- induced Phosphorylated SMAD1/5 activation in fibroblasts from individuals with FOP in a dose- dependent manner. Thus, CDD-2789 is a valuable tool compound for further investigation of the biological functions of ALK2 and ALK1 and the therapeutic potential of specific inhibition of ALK2.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections
    Modukuri, Ram K.
    Yu, Zhifeng
    Tan, Zhi
    Hai Minh Ta
    Ucisik, Melek Nihan
    Jin, Zhuang
    Anglin, Justin L.
    Sharma, Kiran L.
    Nyshadham, Pranavanand
    Li, Feng
    Riehle, Kevin
    Faver, John C.
    Duong, Kevin
    Nagarajan, Sureshbabu
    Simmons, Nicholas
    Palmer, Stephen S.
    Teng, Mingxing
    Young, Damian W.
    Yi, Joanna S.
    Kim, Choel
    Matzuk, Martin M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (22)
  • [42] Discovery of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines as potent anaplastic lymphoma kinase (ALK) inhibitors
    Chen, Changwei
    Pa, Peichen
    Deng, Ziyang
    Wang, Dahai
    Wu, Qifan
    Xu, Lei
    Hou, Tingjun
    Cui, Sunliang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (07) : 912 - 916
  • [43] Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries
    Suzuki, Takayoshi
    Ota, Yosuke
    Ri, Masaki
    Bando, Masashige
    Gotoh, Aogu
    Itoh, Yukihiro
    Tsumoto, Hiroki
    Tatum, Prima R.
    Mizukami, Tamio
    Nakagawa, Hidehiko
    Iida, Shinsuke
    Ueda, Ryuzo
    Shirahige, Katsuhiko
    Miyata, Naoki
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 9562 - 9575
  • [44] Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma
    Smil, David
    Wong, Jong Fu
    Williams, Eleanor P.
    Adamson, Roslin J.
    Howarth, Alison
    McLeod, David A.
    Mamai, Ahmed
    Kim, Soyoung
    Wilson, Brian J.
    Kiyota, Taira
    Aman, Ahmed
    Owen, Julie
    Poda, Gennady
    Horiuchi, Kurumi Y.
    Kuznetsova, Ekaterina
    Ma, Haiching
    Hamblin, J. Nicole
    Cramp, Sue
    Roberts, Owen G.
    Edwards, Aled M.
    Uehling, David
    Al-awar, Rima
    Bullock, Alex N.
    O'Meara, Jeff A.
    Isaac, Methvin B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (17) : 10061 - 10085
  • [45] NXP900, a novel YES1/SRC Kinase Inhibitor in Phase 1 Dose Escalation, Demonstrates Potent Synergy with ALK Inhibitors in ALK Resistant Cell Lines
    Unciti-Broceta, A.
    Poradosu, E.
    Carragher, N. O.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S92 - S92
  • [46] Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants
    Chen, Wenteng
    Guo, Xiao
    Zhang, Can
    Ke, Di
    Zhang, Guolin
    Yu, Yongping
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 183
  • [47] Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design
    Fujimori, Ikuo
    Wakabayashi, Takeshi
    Murakami, Morio
    Okabe, Atsutoshi
    Ishii, Tsuyoshi
    McGrath, Aaron
    Zou, Hua
    Saikatendu, Kumar Singh
    Imoto, Hiroshi
    ACS OMEGA, 2020, 5 (49): : 31984 - 32001
  • [48] Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors
    Wurz, Ryan P.
    Sastri, Christine
    D'Amico, Derin C.
    Herberich, Brad
    Jackson, Claire L. M.
    Pettus, Liping H.
    Tasker, Andrew S.
    Wu, Bin
    Guerrero, Nadia
    Lipford, J. Russell
    Winston, Jeffrey T.
    Yang, Yajing
    Wang, Paul
    Nguyen, Yen
    Andrews, Kristin L.
    Huang, Xin
    Lee, Matthew R.
    Mohr, Christopher
    Zhang, J. D.
    Reid, Darren L.
    Xu, Yang
    Zhou, Yihong
    Wang, Hui-Ling
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (22) : 5580 - 5590
  • [49] Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1
    Degnan, Andrew P.
    Kumi, Godwin K.
    Allard, Christopher W.
    Araujo, Erika, V
    Johnson, Walter L.
    Zimmermann, Kurt
    Pearce, Bradley C.
    Sheriff, Steven
    Futran, Alan
    Li, Xin
    Locke, Gregory A.
    You, Dan
    Morrison, John
    Parrish, Karen E.
    Stromko, Caitlyn
    Murtaza, Anwar
    Liu, Jinqi
    Johnson, Benjamin M.
    Vite, Gregory D.
    Wittman, Mark D.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (03): : 443 - 450
  • [50] Preclinical Characterization of BCX9250, a Potent Oral Activin receptorlike kinase-2 (ALK2) Inhibitor, for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
    Chen, Xilin
    Cheng, Xiaogang
    Kallogg-Yelder, Debra
    Liu, Qinde
    Muppa, Saritha
    Parker, Cynthia
    Raman, Krishnan
    Kotian, Pravin
    Babu, Yarlagadda
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 96 - 96